Microencapsulated DNA for vaccination and gene therapy

Details Microencapsulated DNA for vaccination and gene therapy Microencapsulated DNA for vaccination and gene therapy

1996-11-12

2003-12-23

Nguyen, Dave T. (Department: 1632)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C424S489000, C424S490000, C435S320100, C435S455000

Reexamination Certificate

active

06667294

ABSTRACT:

FIELD OF INVENTION
The present invention relates to microencapsulated DNA, to vaccines comprising microencapsulated DNA, to methods of vaccination and to methods of gene therapy comprising administration of DNA in microparticles, to methods of preparing microparticles containing DNA and to dried compositions comprising DNA-containing particles.
TECHNOLOGY REVIEW
The biodegradable polymer poly (DL-lactide-co-glycolide) (PLG) has been used for many years by the pharmaceutical industry to deliver drugs and biologicals in microparticulate form in vivo. The United States FDA has recently approved a PLG microsphere 30-day delivery system for leuprolide acetate (Lupran Depot (registered trade mark)) to be used in the treatment of prostate cancer. A useful review of the potential of polymer microencapsulation technology for vaccine use is found in Vaccine, 1994, volume 12, number 1, pages 5-11, by William Morris et al.
As an alternative to encapsulation, it is also known to deliver antigens in phospholipid vesicles called liposomes, as described for example by Eppstein, D. A et al in Crit. Rev. Ther. Drug Carrier Syst. 1988, 5(2), pages 99-139. It is reported that a number of antigens have been delivered intraperitoneally using liposomes, including cholera toxin, malaria sporozoite protein and tetanus toxoid, and that influenza antigen has been delivered intra-nasally.
It is also known that, in certain circumstances, injection of naked DNA into tissue can lead to expression of a gene product coded by that DNA. For example, in 1984, work at the United States NIH reported that intrahepatic injection of naked, cloned plasmid DNA for squirrel hepatitis produced both viral infection and the formation of anti-viral antibodies in the squirrels.
WO-A-95/05853 describes methods, compositions and devices for administration of naked polynucleotides which encode biologically active peptides. This published application describes, inter alia, the injection of naked DNA coding for an immunogenic antigen with the aim of raising antibodies in the recipient of the naked DNA.
Liposomal delivery of DNA is also known, and is described, for example, in EP-A-0475178.
An alternative method for obtaining expression of a desired gene product is described in EP-A-0161640, in which mouse cells expressing bovine growth hormone are encapsulated and implanted into a cow to increase milk production therein.
EP-A-0248531 describes encapsulating linear poly (I:C) in microcapsules and using these to induce production of interferon.
WO-A-94/23738 purports to describe a microparticle containing DNA in combination with a conjugate that facilitates and targets cellular uptake of the DNA. In working examples, bombardment of cells by microparticles containing Tungsten is described. These examples appear little different to conventional bombardment of cells with DNA-coated metal particles. Furthermore, sonication is proposed in microparticle manufacture, a step that is known to risk DNA damage but the presented data is inadequate and inappropriate to determine the integrity of the encapsulated DNA.
SUMMARY OF THE INVENTION
In the present invention, it is desired to deliver, in vivo, DNA encoding proteins with immunogenic, enzymatic or other useful biological activity, usually under the control of an active eukaryotic promoter. Objects of the invention include improvement on vaccination therapies known in the art and improvement upon prior art gene therapy methods.
Improvement of or alternatives to existing compositions and methods are desirable as these existing methods are known to contain a number of drawbacks.
WO-A-95/05853 describes administration of naked polynucleotides which code for desired gene products. However, the compositions and methods in this publication are suitable only for injection, requiring sterile procedures, being in itself an unpleasant and awkward route of administration.
WO-A-94/23738 purports to provide a process in which encapsulated DNA is released from the particles in the body of the recipient and then taken up by cells, although no accomplished in vivo examples are presented.
The invention seeks to provide novel compositions and methods of administration thereof that improve upon existing vaccination and gene therapy techniques and are effective in vivo, or at least overcome some of the problems or disadvantages identified in known compositions and methods.
It is known that DNA is readily damaged so that it is no longer capable of inducing expression of a gene product. Surprisingly, the inventors have succeeded in devising a technique for encapsulation of DNA within polymer particles, such that the DNA retains sufficient integrity to induce expression of a gene product coded thereby. The inventors have also succeeded in devising a DNA-containing microparticle suitable for mammalian vaccination or for gene therapy.


REFERENCES:
patent: 3523906 (1970-08-01), Vrancken et al.
patent: 4262090 (1981-04-01), Colby, Jr. et al.
patent: 4293539 (1981-10-01), Ludwig et al.
patent: 4623588 (1986-11-01), Nuwayser et al.
patent: 4652441 (1987-03-01), Okada et al.
patent: 4711782 (1987-12-01), Okada et al.
patent: 4741872 (1988-05-01), De Luca et al.
patent: 4818542 (1989-04-01), DeLuca et al.
patent: 4853226 (1989-08-01), Machida et al.
patent: 4897268 (1990-01-01), Tice et al.
patent: 4917893 (1990-04-01), Okada et al.
patent: 4933105 (1990-06-01), Fong
patent: 5061492 (1991-10-01), Okada et al.
patent: 5075109 (1991-12-01), Tice et al.
patent: 5084553 (1992-01-01), Hess et al.
patent: 5100669 (1992-03-01), Hyon et al.
patent: 5160745 (1992-11-01), De Luca et al.
patent: 5407609 (1995-04-01), Tice et al.
patent: 5417986 (1995-05-01), Reid et al.
patent: 5460831 (1995-10-01), Kossovsky et al.
patent: 5529777 (1996-06-01), Andrianov et al.
patent: 5531925 (1996-07-01), Landh et al.
patent: 5540937 (1996-07-01), Billot et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5585050 (1996-12-01), Jorda et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5622649 (1997-04-01), Hunter et al.
patent: 5639473 (1997-06-01), Grinstaff et al.
patent: 5643578 (1997-07-01), Robinson et al.
patent: 5643605 (1997-07-01), Cleland et al.
patent: 5648095 (1997-07-01), Illum et al.
patent: 5650173 (1997-07-01), Ramstack et al.
patent: 5654008 (1997-08-01), Herbert et al.
patent: 5656469 (1997-08-01), Tresco et al.
patent: 5665383 (1997-09-01), Grinstaff et al.
patent: 5783567 (1998-07-01), Hedley et al.
patent: 5814344 (1998-09-01), Tice et al.
patent: 5820883 (1998-10-01), Tice et al.
patent: 5853763 (1998-12-01), Tice et al.
patent: 5942252 (1999-08-01), Tice et al.
patent: 6024983 (2000-02-01), Tice et al.
patent: 6080429 (2000-06-01), Cleland et al.
patent: 6096331 (2000-08-01), Desai et al.
patent: 6159502 (2000-12-01), Russell-Jones et al.
patent: 6217908 (2001-04-01), Mathiowitz et al.
patent: 6248720 (2001-06-01), Mathiowitz et al.
patent: 2126685 (1994-05-01), None
patent: 0 027 662 (1981-04-01), None
patent: 0127713 (1984-12-01), None
patent: 0 145 240 (1985-06-01), None
patent: 0 161 640 (1985-11-01), None
patent: 0 179 023 (1986-04-01), None
patent: 0 248 531 (1987-12-01), None
patent: 0 250 038 (1987-12-01), None
patent: 0257915 (1988-03-01), None
patent: 0 258 749 (1988-03-01), None
patent: 0 263 490 (1988-04-01), None
patent: 0266119 (1988-05-01), None
patent: 0302582 (1989-02-01), None
patent: 0330180 (1989-08-01), None
patent: 0333523 (1989-09-01), None
patent: 0 334 062 (1989-09-01), None
patent: 0 374 531 (1990-06-01), None
patent: 0 451 390 (1991-10-01), None
patent: 0451391 (1991-10-01), None
patent: 0 467 389 (1992-01-01), None
patent: 0471036 (1992-02-01), None
patent: 0 475 178 (1992-03-01), None
patent: 0531497 (1993-03-01), None
patent: 0 635 261 (1995-01-01), None
patent: 0706792 (1996-04-01), None
patent: 0737750 (1996-10-01), None
patent: 0 779 072 (1997-06-01), None
patent: 2185979 (1987-08-01), None
patent: 2 234 896 (1991-02-01), None
patent: 2 265 311 (1993-09-01), None
patent: 2 310 801 (1997-09-01), None
patent: WO 90/11092 (1990-10-01), None
patent: 91/11092 (1990-10-01), None

Affiliated with

Also associated with

Rating

Microencapsulated DNA for vaccination and gene therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Microencapsulated DNA for vaccination and gene therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Microencapsulated DNA for vaccination and gene therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3119304